Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
52.87
+0.05 (0.09%)
At close: May 1, 2026, 4:00 PM EDT
52.60
-0.27 (-0.52%)
After-hours: May 1, 2026, 7:39 PM EDT
Soleno Therapeutics Revenue
In the year 2025, Soleno Therapeutics had annual revenue of $190.41M. Soleno Therapeutics had revenue of $91.73M in the quarter ending December 31, 2025.
Revenue (ttm)
$190.41M
Revenue Growth
n/a
P/S Ratio
14.36
Revenue / Employee
$1,046,181
Employees
182
Market Cap
2.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 190.41M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tarsus Pharmaceuticals | 451.36M |
| Arcutis Biotherapeutics | 376.07M |
| Nektar Therapeutics | 55.23M |
| Immunome | 6.94M |
| Celldex Therapeutics | 1.55M |
SLNO News
- 2 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Soleno Therapeutics, Inc. Lawsuit - SLNO - GlobeNewsWire
- 18 days ago - Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers - GlobeNewsWire
- 18 days ago - Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders? - PRNewsWire
- 24 days ago - SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline - GlobeNewsWire
- 26 days ago - Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover - Reuters
- 27 days ago - Neurocrine to Buy Soleno for $2.9 Billion - WSJ
- 27 days ago - Neurocrine to buy Soleno Therapeutics for $2.9 billion - Reuters
- 27 days ago - Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PRNewsWire